Cargando…
Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065670/ https://www.ncbi.nlm.nih.gov/pubmed/35508524 http://dx.doi.org/10.1038/s41598-022-11103-0 |
_version_ | 1784699635331235840 |
---|---|
author | Schäfer, Eik Scheer, Christian Saljé, Karen Fritz, Anja Kohlmann, Thomas Hübner, Nils-Olaf Napp, Matthias Fiedler-Lacombe, Lizon Stahl, Dana Rauch, Bernhard Nauck, Matthias Völker, Uwe Felix, Stephan Lucchese, Guglielmo Flöel, Agnes Engeli, Stefan Hoffmann, Wolfgang Hahnenkamp, Klaus Tzvetkov, Mladen V. |
author_facet | Schäfer, Eik Scheer, Christian Saljé, Karen Fritz, Anja Kohlmann, Thomas Hübner, Nils-Olaf Napp, Matthias Fiedler-Lacombe, Lizon Stahl, Dana Rauch, Bernhard Nauck, Matthias Völker, Uwe Felix, Stephan Lucchese, Guglielmo Flöel, Agnes Engeli, Stefan Hoffmann, Wolfgang Hahnenkamp, Klaus Tzvetkov, Mladen V. |
author_sort | Schäfer, Eik |
collection | PubMed |
description | We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization. |
format | Online Article Text |
id | pubmed-9065670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90656702022-05-04 Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection Schäfer, Eik Scheer, Christian Saljé, Karen Fritz, Anja Kohlmann, Thomas Hübner, Nils-Olaf Napp, Matthias Fiedler-Lacombe, Lizon Stahl, Dana Rauch, Bernhard Nauck, Matthias Völker, Uwe Felix, Stephan Lucchese, Guglielmo Flöel, Agnes Engeli, Stefan Hoffmann, Wolfgang Hahnenkamp, Klaus Tzvetkov, Mladen V. Sci Rep Article We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization. Nature Publishing Group UK 2022-05-04 /pmc/articles/PMC9065670/ /pubmed/35508524 http://dx.doi.org/10.1038/s41598-022-11103-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Schäfer, Eik Scheer, Christian Saljé, Karen Fritz, Anja Kohlmann, Thomas Hübner, Nils-Olaf Napp, Matthias Fiedler-Lacombe, Lizon Stahl, Dana Rauch, Bernhard Nauck, Matthias Völker, Uwe Felix, Stephan Lucchese, Guglielmo Flöel, Agnes Engeli, Stefan Hoffmann, Wolfgang Hahnenkamp, Klaus Tzvetkov, Mladen V. Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title | Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title_full | Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title_fullStr | Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title_full_unstemmed | Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title_short | Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection |
title_sort | course of disease and risk factors for hospitalization in outpatients with a sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065670/ https://www.ncbi.nlm.nih.gov/pubmed/35508524 http://dx.doi.org/10.1038/s41598-022-11103-0 |
work_keys_str_mv | AT schafereik courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT scheerchristian courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT saljekaren courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT fritzanja courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT kohlmannthomas courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT hubnernilsolaf courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT nappmatthias courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT fiedlerlacombelizon courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT stahldana courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT rauchbernhard courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT nauckmatthias courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT volkeruwe courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT felixstephan courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT luccheseguglielmo courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT floelagnes courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT engelistefan courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT hoffmannwolfgang courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT hahnenkampklaus courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection AT tzvetkovmladenv courseofdiseaseandriskfactorsforhospitalizationinoutpatientswithasarscov2infection |